

Immunospecific Reduction of Antioligonucleotide Antibody-Forming Cells with a Tetrakis-oligonucleotide Conjugate (LJP 394), a Therapeutic Candidate for the Treatment of Lupus Nephritis

David S. Jones,* Paul A. Barstad, Mark J. Feild, John P. Hachmann, Merle S. Hayag, Kenneth W. Hill, G. Michael Iverson, Douglas A. Livingston, Moorthy S. Palanki, Anthony R. Tibbetts, Lin Yu, and Stephen M. Coutts

La Jolla Pharmaceutical Company, 6455 Nancy Ridge Drive, San Diego, California 92121

Received December 27, 1994*

A discrete tetravalent conjugate, 7a (LJP 394), consisting of four oligonucleotides attached to a common carrier or platform was prepared. Single-stranded oligonucleotide 20-mers consisting of alternating deoxycytidine-deoxyadenosine nucleotides, (CA)₁₀, were attached to a tetrabromoacetylated platform by displacement with sulfhydryl-terminated linkers. The tetrabromoacetylated platform 3a was synthesized in three steps using triethylene glycol bis-(chloroformate). The single-stranded conjugate was characterized by polyacrylamide gel electrophoresis, DNA sequencing, phosphate analysis, carbon and nitrogen combustion analysis, and correlation of stoichiometry to conversion in the conjugation process. HPLC and capillary electrophoretic methods were developed to evaluate purity. The tetrakis, single-stranded oligonucleotide 20-mer consisting of alternating thymidine-deoxyguanosine nucleotides, (TG)₁₀. The double-stranded conjugate LJP 394 was characterized by melt temperature and hyperchromicity, phosphate analysis, and carbon and nitrogen combustion analysis. LJP 394 inhibits binding of DNA to anti-double-stranded oligonucleotide antibodies and reduces anti-oligonucleotide-specific plaque (antibody)-forming cells in an immunized mouse model by a proposed mechanism involving cross-linking B cell surface immunoglobins.

Introduction

Multiple copies of a hapten attached covalently to a nonimmunogenic polymeric backbone can down regulate, or tolerize, those B lymphocytes producing antibodies that bind the hapten, rendering them nonresponsive to haptenated immunogens.¹ The result is a decrease in the amount of antibody produced against the hapten. Molecules such as these, which suppress antibody production by B cells, are called toleragens. For example, 2,4-dinitrophenyl (DNP) groups attached to the D-lysines in polymers consisting of D-amino acids can suppress IgG production in animals which have been immunized with DNP-derivatized proteins. Such findings suggested a therapeutic approach for treatment of autoimmune disorders by specifically tolerizing B cells. Systemic lupus erythematosus (SLE) is characterized by antibodies to a number of nuclear antigens. Specifically, antibodies to double-stranded DNA (anti-ds-DNA) are thought to cause lupus nephritis.² We have shown that synthetic double-stranded oligonucleotides (ds-ON) cross-react with anti-ds-DNA.³ Our approach toward a therapy for SLE involves the use of ds-ON conjugates with nonimmunogenic carriers, also referred to as platforms, to inactivate B cells which synthesize anti-ds-DNA antibodies.

We recently reported the synthesis of a tetrakis conjugate, LJP 249, which consists of four double-stranded oligonucleotides attached to a poly(ethylene glycol) "valency" platform.⁴ That conjugate was used to demonstrate tolerance in an immunized mouse model. We have since prepared a variety of analogues on various polymeric and nonpolymeric platforms with the

premise that use of a smaller platform would yield fully defined conjugates, which would facilitate manufacturing, analysis, purity, and, ultimately, pharmaceutical regulatory issues.


We now wish to report on the synthesis and characterization of a new conjugate, 7a (LJP 394), which has entered human clinical trials. This conjugate consists of four double-stranded oligonucleotides attached to a new fully defined, tetrakis platform consisting of triethylene glycol which has been modified with alkylamide-branching groups used as tethers for attachment of oligonucleotides.

Discussion

In our continuing efforts to develop a therapy for lupus nephritis, our objective has been to develop a conjugate of four double-stranded oligonucleotides on a completely defined, nonpolymeric platform. LJP 394 (7a) is one such analogue, which was selected for its ability to tolerize anti-ds-DNA antibody-forming cells. In addition to its biological activity, it was selected as our primary therapeutic candidate on the basis of the following criteria. (a) The platform, with four thiol-reactive groups attached, can be synthesized efficiently and in high purity. (b) The platform has sufficient solubility in water to undergo conjugation reactions. (c) The conjugate and its expected metabolites are predicted to be nontoxic.

The rationale for the design of LJP 394 was based on our previous work involving LJP 249, which has a poly(ethylene glycol)-based platform.⁴ Our objective was to replace the polymer-based platform with a discrete nonpolymeric platform. The oligonucleotide length and sequence, duplexes of 20 base pairs (10 repeating CA

* Abstract published in *Advance ACS Abstracts*, May 1, 1995.

Scheme 1. Synthesis of Bromoacetylated Platform^a

^a (a) Carbonyldiimidazole, diethylenetriamine, EtOAc; (b) triethylene glycol bis(chloroformate), pyridine, DMF; (c) Pd/C, cyclohexene, EtOAc; (d) 4-nitrophenyl bromoacetate, NaHCO₃, dioxane, H₂O.

units base paired with 10 repeating TG units),⁵ was not changed. This sequence was chosen for LJP 249 on the basis of the ability of unconjugated duplexes to bind human SLE serum.^{3,6} The rationale for choosing to attach four copies of the oligonucleotide to the nonimmunogenic carrier was also a carryover from LJP 249 and was based on the strategy of cross-linking surface antibodies on B cells. While an oligovalent conjugate was desired, we wanted to limit the size of the conjugate in order to avoid producing a T-independent antigen.⁷ In addition, the valency was limited by the need to synthesize a discrete, isolatable compound. Since there are possible side reactions in the conjugation step, the more reactive attachment points there are, the more difficult it becomes to achieve a reasonable yield of fully substituted and fully characterizable material. By branching each end of a bifunctional molecule (triethylene glycol), we were able to attach four copies of oligonucleotides.

The synthesis of the bromoacetylated platform, compound 3, is diagramed in Scheme 1. CBZ-aminocaproic acid is commercially available. Activation of 2 equiv of CBZ-aminocaproic acid with carbonyldiimidazole followed by addition of 1 equiv of diethylenetriamine in the presence of 2 equiv of Et₃N resulted in the selective formation of 1, which was isolated by crystallization in 75% yield. Triethylene glycol bis(chloroformate) was added to 2 equiv of compound 1 in the presence of pyridine in DMF to provide compound 2. The CBZ protecting groups were removed using catalytic transfer hydrogenolysis⁸ with palladium on carbon in ethanol and cyclohexane, and the resulting tetraamino platform was acylated with 4-nitrophenyl bromoacetate to provide 3a. 4-Nitrophenyl bromoacetate was prepared by condensing bromoacetic acid with 4-nitrophenol in the presence of DCC.⁹ The ¹⁴C-labeled platform 3b was prepared similarly from [¹⁴C]bromoacetic acid.¹⁰

Compound 4, an oligonucleotide 20-mer comprised of the repeating sequence of deoxycytidine-deoxyadenosine units, (CA)₁₀,⁶ with a disulfide-protected thiol linker attached to the 5'-end, was prepared as previously described.⁴ There are numerous examples of oligonucleotides modified with thiol linkers that have been attached to other molecules to form oligonucleotide conjugates.¹¹ Our approach allows us to use the trityl group of 4 as a hydrophobic handle which facilitates purification of modified full length oligonucleotide from failure sequences which do not contain the 5'-linker. A

thiol is subsequently generated by reduction of the disulfide bond under mild conditions and in high yield.

Scheme 2 describes the conjugation and annealing processes used to prepare LJP 394. Reduction of disulfide 4 was accomplished with tributylphosphine¹² in pH 5 sodium acetate buffer, giving rise to thiol-modified oligonucleotide 5. Compound 5 was isolated by precipitation using an equal volume of isopropyl alcohol.¹³

A series of small scale conjugation reactions were monitored by HPLC¹⁴ to determine optimal conditions and study the effect of stoichiometry on product distribution. Optimal conditions for the conjugation reaction were determined to be addition of a solution of 1 equiv of platform 3a in 9/1 methanol/H₂O to 4 equiv of 5 in 0.1 M pH 10 sodium borate which had been sparged with helium to remove oxygen to give 6a. The reaction required a pH above 8 to proceed at a reasonable rate. At pH 10, the reaction was complete in 1–2 h as evidenced by no further conversion to product. Prolonged reaction led to no degradation of product or change in HPLC profile, so we now generally allow the reaction to go overnight to insure completeness.

The single-stranded conjugate 6a was characterized by correlation of stoichiometry to conversion, polyacrylamide gel electrophoresis, DNA sequencing, phosphorus analysis, carbon and nitrogen combustion analysis, and mass spectrometry. The fully substituted conjugate, with 4 oligonucleotides/platform, was initially identified by the HPLC profile of reactions substoichiometric in oligonucleotide.¹⁵ Addition of substoichiometric amounts of 5 (2.16–3.88 equiv) leads to mixtures containing varying amounts of conjugates with fewer than four oligonucleotides attached (see Figure 1). As the ratio of 5 to 3a became closer to 4 to 1 (stoichiometric), the peaks of lesser substitution or shorter retention time were converted to the longest retention time peak. When more than 4 equiv were added, there was no evidence of further conversion to higher molecular weight species. These results indicated that the product of retention time of 14.6 min was the desired fully substituted tetramer. Polyacrylamide gel electrophoresis supported the structure 6a, in that the product ran more slowly than the reference 20-mers, (TG)₁₀ and compound 4, as expected for a molecule of that size (see Figure 2). The base sequence was confirmed by Maxam-Gilbert sequencing.¹⁶ Further support for the structure 6a was obtained by electrospray mass spectrometry.¹⁷

Antibody-Forming Cells with Therapeutic Candidate for

erle S. Hayag, Kenneth W. Hill,
y R. Tibbetts, Lin Yu, and

ia 92121

our oligonucleotides attached to
ligonucleotide 20-mers consisting
(TG)₁₀, were attached to a tetrabrom-
s using triethylene glycol bis-
terized by polyacrylamide gel
nd nitrogen combustion analysis,
on process. HPLC and capillary

The tetrakis, single-stranded
complementary single-stranded
xyguanosine nucleotides, (TG)₁₀.
y melt temperature and hyper-
sion analysis. LJP 394 inhibits
dies and reduces anti-oligonucle-
mouse model by a proposed
bins.


use of a smaller platform would yield fully
gates, which would facilitate manufactur-
purity, and, ultimately, pharmaceutical
sues.

ish to report on the synthesis and charac-
a new conjugate, 7a (LJP 394), which has
an clinical trials. This conjugate consists
le-stranded oligonucleotides attached to a
fined, tetrakis platform consisting of tri-
col which has been modified with alkyl-
ing groups used as tethers for attachment
otides.

ntinuing efforts to develop a therapy for
itis, our objective has been to develop a
four double-stranded oligonucleotides on a
efined, nonpolymeric platform. LJP 394
such analogue, which was selected for its
erize anti-ds-DNA antibody-forming cells.
to its biological activity, it was selected as
therapeutic candidate on the basis of the
teria. (a) The platform, with four thiol-
ips attached, can be synthesized efficiently
purity. (b) The platform has sufficient
water to undergo conjugation reactions. (c)
ite and its expected metabolites are pre-
nontoxic.

ial for the design of LJP 394 was based on
work involving LJP 249, which has a poly-
col)-based platform.⁴ Our objective was to
polymer-based platform with a discrete
ic platform. The oligonucleotide length and
uplexes of 20 base pairs (10 repeating CA

in Chemical Society

Scheme 2. Synthesis of Oligonucleotide Conjugate^a

^a (a) Tributylphosphine, pH 5 100 mM sodium acetate; (b) 3, pH 10 100 mM sodium borate; (c) (TG)₁₀, pH 7.2 phosphate-buffered saline.




Figure 1. HPLC chromatograms of crude conjugate 6a: chromatogram A, 2.16 mol equiv of 5/mol of 3a; chromatogram B, 3.88 mol equiv of 5/mol of 3a; reaction profiles at 1 h time point; GenPak FAX column (60 °C, 1 mL/min, 260 nm; gradient, (A) 0.05 M pH 7.5 sodium phosphate, 1/9 MeOH/H₂O, (B) 0.05 M pH 7.5 sodium phosphate, 1 M NaCl, 1/9 MeOH/H₂O; 30–70% B over 0–16 min).

The extinction coefficient for 6a was determined by three independent methods:¹⁸ correlation of absorbance at 260 nm to (a) the phosphorus analysis,¹⁹ (b) the carbon and nitrogen combustion analyses, and (c) the ¹⁴C counts in a preparation of 6b, which was made using 4-nitrophenyl bromo[1-¹⁴C]acetate¹⁰ of known specific activity. All three calculated extinction coefficients agreed to within 3%.

LJP 394 (7a) was prepared by annealing single-stranded conjugate 6a with a slight excess of complementary (TG)₁₀. The two components were mixed in PBS, and the solution was heated to 70 °C and allowed to cool slowly to room temperature. The mixture was analyzed by HPLC to ensure that there was a slight excess of (TG)₁₀. If no excess (TG)₁₀ was detected, the process was repeated after adding more (TG)₁₀.

A B C D

Figure 2. Autoradiogram of an 8% polyacrylamide gel, 3'-end labeled with ³²P and terminal transferase: lane A, (TG)₁₀; lane B, compound 4; lane C, crude reaction; lane D, purified 6a.

The extinction coefficient for 7a (LJP 394) was determined by three methods:¹⁸ correlation of absorbance at 260 nm to (a) the phosphorus analysis,¹⁹ (b) the carbon combustion analysis, and (c) the ¹⁴C counts in a preparation of 7b, which was made by annealing 6b with (TG)₁₀. All three calculated extinction coefficients agreed to within 4%.

Purities of both the single-stranded conjugate 6a and the double-stranded conjugate 7a (LJP 394) were examined by a number of methods. The methods which best resolve 6a are ion exchange HPLC and capillary electrophoresis (CE) using polyacrylamide gel-filled capillaries. Ion exchange HPLC has proved to be the method of choice for analyses of both single- and double-





Figure 3. HPLC chromatogram of purified single-stranded conjugate 6a on a NucleoPac column (55 °C, 2.5 mL/min, 260 nm; gradient, (A) pH 7.5 50 mM sodium phosphate, 1 mM EDTA, 5/95 CH₃CN/H₂O, (B) pH 7.5 50 mM sodium phosphate, 1 mM EDTA, 1.0 M NaCl, 5/95 CH₃CN/H₂O; 30% B, 0–1 min; 30–71% B, 1–1.5 min; 71–80% B, 1.5–12 min). Shoulders on front and back of peak are thought to be related species missing one or more bases on one or more of the oligonucleotides.




Figure 4. Capillary electrophoretogram of purified 6a on a Beckman P/ACE 2100 instrument using a rigid polyacrylamide-filled capillary (100 $\mu\text{m} \times 37$ cm; Beckman Instruments; PN 338480, 30 °C, 260 nm; field strength, 300 V/cm; electrokinetic injection, 6 s at 7.5 kV) with oligonucleotide standards T₂₀ and T₄₀: A, T₂₀; B, T₄₀; C, 6a.

stranded conjugates. We found it difficult to maintain reproducibility using the CE method. Figure 3 shows an ion exchange HPLC chromatogram of 6a, Figure 4 shows a typical CE chromatogram of 6a, and Figure 5 shows an ion exchange HPLC chromatogram of 7a (LJP 394).

The serum stability of LJP 394 was examined using agarose gels, visualized with ethidium bromide. LJP




Figure 5. HPLC chromatogram of double-stranded conjugate 7a (LJP 394) on a GenPak FAX column (40 °C, 0.75 mL/min, 260 nm; gradient (A) pH 7.5 50 mM sodium phosphate, 1 mM EDTA, 1/9 MeOH/H₂O, (B) pH 7.5 50 mM sodium phosphate, 1 mM EDTA, 1.0 M NaCl, 1/9 MeOH/H₂O; 20–82% B, 0–22.11 min).

394 was found to be relatively stable against human serum nucleases in that the mobility or intensity of the bands did not change after 4 h of incubation at 37 °C in serum from normal or lupus donors. The compound was completely degraded, however, within 2–4 h by sera from lupus mice. No mammalian cellular nucleases were studied, since the molecule is thought to operate on the exterior (surface antibody receptors) of B cells and does not have to enter cells for its biological activity.

In Vivo Biology. Mice (C57BL/6) were immunized (as previously described)⁴ with a conjugate of double-stranded oligonucleotides (CA)₂₅(TG)₂₅ attached to KLH. Neither DNA nor synthetic oligonucleotides are immunogenic because they lack T cell epitopes and cannot generate the necessary help from CD4[+] T cells required for a functional antibody response. The purpose of making a conjugate between the highly immunogenic protein KLH and synthetic ds-ON was to provide the ds-ON with T cell epitopes. Since the B cell repertoire of C57BL/6 mice recognizes the ds-ON, it can mount an antibody response against the ds-ON-KLH conjugate. These antibodies are of high enough affinity to give a positive Farr assay where the radioactive antigen is present at 10⁻⁸ M.

Three weeks after immunization, the mice were injected with LJP 394. A control group was injected with saline after the immunization. Five days later, mice in both groups were boosted with the oligonucleotide-KLH conjugate. Four days later, the spleens were harvested and the number of anti-ds-ON antibody-forming cells was determined. The results, shown in Table 1, show that the treatment of the immunized mice with LJP 394 significantly reduced the number of anti-ds-ON antibody-forming cells in a dose-dependent manner. Thus, these mice were rendered unresponsive (tolerant) to further challenge with an immunogenic form of the oligonucleotide.

The specificity of the treatment was demonstrated with measurements of anti-ds-ON antibodies and anti-KLH antibodies in serum from ds-ON-KLH immunized

A B C D
 Autoradiogram of an 8% polyacrylamide gel, 3'-
 with ³²P and terminal transferase: lane A, (TG)₁₀;
 compound 4; lane C, crude reaction; lane D, purified

extinction coefficient for 7a (LJP 394) was determined by three methods:¹⁸ correlation of absorbance at 260 nm to (a) the phosphorus analysis,¹⁹ (b) combustion analysis, and (c) the ¹⁴C counts per minute of 7b, which was made by annealing (TG)₁₀. All three calculated extinction coefficients agreed to within 4%.

Both the single-stranded conjugate 6a and the double-stranded conjugate 7a (LJP 394) were examined by a number of methods. The methods which were used for 6a are ion exchange HPLC and capillary electrophoresis (CE) using polyacrylamide gel-filled columns. Ion exchange HPLC has proved to be the choice for analyses of both single- and double-

Table 1. Reduction in the Number of Double-Stranded Oligonucleotide-Specific, IgG-Antibody-Forming Cells in Mice Treated with Compound 7 (LJP 394)

dose ^b (nmol)	antibody-forming cells/10 ⁶ spleen cells ^a					
	experiment 1 ^c			experiment 2 ^c		
	mean	(SD)	reduction ^d (%)	mean	(SD)	reduction ^d (%)
none	5562	(2570)		5899	(344)	
5.058	982	(1871)	82.3*	3413	(1604)	42.1
1.686	1867	(1335)	66.4*	222	(725)	96.2*
0.562	2247	(1606)	59.6*	1492	(2264)	74.7*
0.187	6109	(2545)	0	5421	(832)	8.1
0.062	4045	(1411)	27.3	5077	(1946)	13.9
0.021	4578	(2475)	17.7	7023	(679)	0
0.007	5930	(847)	0	4159	(2688)	29.5

^a The number of ds-ON-specific antibody-forming cells was determined in two separate experiments. ^b Dose of LJP 394 per mouse (MW 54 172 g/mol). ^c The data were analyzed by analysis of variance (ANOVA). The groups that were significantly different from the control group are marked with an asterisk. For experiment 1, $P = 0.0117$, and for experiment 2, $P = 0.0001$. ^d Percent reduction was determined by dividing the difference between the number of antibody-forming cells in the treated group and the control group by the number of antibody-forming cells in the control group and multiplying by 100.

mice which had been tolerized with LJP 394. There was no reduction in the anti-KLH (carrier) response as determined in an ELISA assay,²⁰ however, there was a significant dose-dependent reduction in the anti-ds-ON response as determined by a Farr assay²¹ with a mean ED₅₀ value of 21 ± 14 μ g/mouse (0.389 ± 0.259 nmol/mouse). Thus, the toleragen was specific for down regulating the anti-ds-ON antibody response without affecting the immune response to the protein carrier in the immunogen KLH.

In conclusion, we have synthesized and characterized a nonpolymeric, oligovalent double-stranded oligonucleotide-platform conjugate, 7a (LJP 394). This conjugate retains the biological activity of its polymeric, poly(ethylene glycol)-based prototype, in that it reduces anti-double-stranded oligonucleotide antibody-forming spleen cells when injected in mice which have been immunized to make anti-double-stranded oligonucleotide antibodies. These, and other, results have led us to initiate clinical trials as a therapy for lupus nephritis.

Experimental Section

N-CBZ-aminocaproic acid, carbonyldiimidazole, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), diethylenetriamine, triethylene glycol bis(chloroformate), bromoacetic acid, and 4-nitrophenol were purchased from Aldrich Chemical Co.

Silica gel (230–400 mesh ASTM) was purchased from Baxter. Q-Sepharose was purchased from Pharmacia. Fractogel EMD-DEAE 650(S) (particle size 0.025–0.040 mm) was purchased from EM Separations. ProteinPac Q-HR15 ion exchange packing was purchased from Waters. GenPak FAX HPLC columns were purchased from Waters, and NucleoPac PA-100 HPLC columns (P/N 43010) were purchased from Dionex. Shodex HPLC columns KW802.5 were purchased from Shoko Co. Ltd. TLC was performed on silica gel TLC plates (5554) manufactured by EM Separations. Phosphate-buffered saline (PBS), pH 7.2, was prepared by dissolving 175 g of NaCl, 6.5 g of NaH₂PO₄·H₂O, and 40.9 g of Na₂HPO₄·7H₂O in H₂O and diluting to a final volume of 20 L.

Melting points are reported uncorrected. NMR spectra were recorded on a Bruker AC-300 spectrometer with broad-band probe. DNA synthesis was performed on a Milligen 8800 prep scale DNA synthesizer following the manufacturer's protocols for DNA phosphoramidite synthesis. UV absorbances were measured on a Perkin-Elmer 1-4 spectrophotometer. Melt

curves and hyperchromicity were determined on a Varian Cary 3E spectrophotometer. Elemental analysis were performed by Desert Analytics of Tucson, AZ. Mass spectra were obtained from the Mass Spectroscopy Lab, Department of Chemistry, University of California, Berkeley, CA. Sequencing of oligonucleotides was performed by a modification of the Maxam-Gilbert method.^{16,22}

Bis(phenylmethyl) 8,16-Dioxo-2,9,12,15,22-pentaazatricosanedioate, 1. A solution of 5.05 g (19.0 mmol) of *N*-(carbobenzoyloxy)-6-aminohexanoic acid and 3.09 g (19.0 mmol) of carbonyldiimidazole in 25 mL of EtOAc was stirred for 1.5 h at room temperature, and 1.02 mL (982 mg, 9.52 mmol) of diethylenetriamine was added followed by 2.65 mL (1.93 g, 19.0 mmol) of Et₃N. The mixture was stirred for 4 h, and the solid product which precipitated was collected by filtration. Recrystallization (MeOH/EtOAc) gave 4.27 g (75%) of 1 as a fine grainy solid: mp 132–133 °C; ¹H NMR (CDCl₃) δ 1.33 (m, 4H), 1.52 (m, 4H), 1.64 (m, 4H), 2.18 (t, 4H), 2.73 (t, 4H), 3.16 (m, 4H), 3.35 (m, 4H), 4.96 (bd, s, 2H), 5.09 (s, 4H), 6.13 (bd s, 2H), 7.33 (s, 10H); ¹³C NMR (CD₃OD) δ 26.4, 27.3, 30.5, 36.9, 39.8, 41.5, 48.5, 67.2, 128.6, 128.8, 129.3, 138.3, 158.7, 176.2; IR (KBr pellet, cm⁻¹) 1265, 1533, 1629, 1686, 2946, 3316, 3346; MS (FAB, NBA matrix) m/z 598 (MH⁺) 490, 320; UV (MeOH) 206 ($\epsilon = 1365$), 254 ($\epsilon = 244$), 258 ($\epsilon = 310$), 264 ($\epsilon = 255$). Anal. (C₂₂H₄₇N₅O₈) C, H, N.

Bis(phenylmethyl) 8,13,24,29-tetraoxo-12,25-bis[2-[[1-oxo-6-[[phenylmethoxy]carbonyl]amino]hexyl]amino]ethyl]-14,17,20,23-tetraoxa-2,9,12,25,28,35-hexaazahexatriacontanediolate, 2. A mixture of 2.99 g (5.0 mmol) of 1 and 412 μ L of pyridine in 15.4 mL of DMF was heated until a clear solution was obtained and then kept at 40 °C. To the mixture was added dropwise over 1 min 515 μ L (690 mg, 2.5 mmol) of triethylene glycol bis(chloroformate). The mixture immediately formed a precipitate. The mixture was stirred for 1 h at 40 °C and partitioned between 30 mL of CH₂Cl₂ and 20 mL of water. The CH₂Cl₂ layer was washed with 20 mL of water, dried (Na₂SO₄), filtered, and concentrated. The resulting residue was purified by silica gel chromatography (gradient, 3% MeOH/CH₂Cl₂ to 15% MeOH/CH₂Cl₂) to provide an oil which was crystallized from CH₂Cl₂/EtOAc/heptane to give 2.10 g (60%) of 2 as a white solid: mp 83–85 °C; TLC R_f 0.15 (89/10/1 CH₂Cl₂/MeOH/HOAc); ¹H NMR (CDCl₃) δ 1.31 (m, 8H), 1.52 (m, 8H), 1.62 (m, 8H), 2.20 (m, 8H), 3.20 (m, 8H), 3.39 (s, 16H), 3.62 (s, 4H), 3.68 (m, 4H), 4.26 (m, 4H), 5.08 (s, 8H), 5.32 (bd s, 4H), 7.31 (bd s, 4H), 7.37 (s, 20H); ¹³C NMR (CDCl₃) δ 25.1, 26.2, 26.4, 29.6, 36.0, 36.2, 38.5, 38.8, 40.8, 64.5, 66.4, 69.1, 70.3, 128.0, 128.4, 136.7, 156.5, 156.9, 173.6; IR (KBr pellet, cm⁻¹) 1140, 1238, 1268, 1548, 1642, 1687, 2934, 3035, 3065, 3320; MS (FAB, NBA matrix) m/z 1419 (MN⁺), 1398 (MH⁺), 1353, 1263, 1150; UV (MeOH) 208 ($\epsilon = 41 582$), 258 ($\epsilon = 609$). Anal. (C₇₂H₁₀₄N₁₆O₁₈) C, H, N.

4-Nitrophenyl Bromoacetate. Dicyclohexylcarbodiimide (9.28 g, 45 mmol) was added to a stirred solution of 5.0 g (35.9 mmol) of bromoacetic acid and 8.50 g (61.1 mmol) of 4-nitrophenol in 180 mL of EtOAc at 0 °C. The mixture was stirred for 16 h at 5 °C, and 1 mL of acetic acid was added. The mixture was stirred for 20 min at room temperature and placed in the freezer for 20 min. The solid material was removed by filtration, and the filtrate was concentrated to a viscous oil and crystallized from Et₂O/hexanes to provide 7.73 g (83%) of 4-nitrophenyl bromoacetate as flakes: mp 86–87 °C (lit.⁹ mp 88–91 °C); TLC R_f 0.63 (50/50/1 hexanes/EtOAc/HOAc); ¹H NMR (CDCl₃) δ 4.13 (s, 2H), 7.36 (d, $J = 12$ Hz, 2H), 8.32 (d, $J = 12$ Hz, 2H); ¹³C NMR (CDCl₃) δ 24.9, 122.1, 125.3, 155.5, 164.9; IR (KBr pellet, cm⁻¹) 1770, 2863, 3020, 3074, 3111. Anal. (C₈H₆BrNO₂) C, H, N.

1,2-Ethanedithylbis[oxo-2,1-ethanedithylbis[2-[[6-(bromoacetyl)amino]-1-oxohexyl]amino]ethyl]carbamate, 3a. A solution of 8.0 g (5.7 mmol) of 2 in 50 mL of absolute EtOH and 35 mL of cyclohexene was placed under nitrogen, and 500 mg of 10% Pd on carbon was added. The mixture was refluxed with stirring for 2 h. When cool, the mixture was filtered through Celite and concentrated to give 5.0 g of an oil. The CBZ protecting groups were completely removed as evidenced by NMR: ¹H NMR (50/50 CDCl₃/CD₃OD) δ 1.21 (m, 8H), 1.49

diethylbis(oxy-2,1-ethanediylbis[2-[[6-(bromo-1-oxohexyl)amino]ethyl]carbamate], 3a. A solution of 5.0 g (5.7 mmol) of 2 in 50 mL of absolute EtOH and 10 mL of cyclohexene was placed under nitrogen, and 5000 mg of activated carbon was added. The mixture was refluxed for 2 h. When cool, the mixture was filtered and concentrated to give 5.0 g of an oil. The impurities were completely removed as evidenced by NMR (50/50 CDCl₃/CD₃OD) δ 1.21 (m, 8H), 1.49

Annealing of 6a with (TG)₁₀: Preparation of LJP 394. A mixture of 5489 OD₂₆₀ (210 mg, 7.6 μ mol) of 6a in a volume of 7.7 mL of 0.5x PBS and a mixture 5842 OD₂₆₀ (214 mg, 32 μ mol) of (TG)₁₀ in 1.94 mL of H₂O were mixed and heated at 70 °C in a water bath for 5 min. The bath was allowed to cool to room temperature, and the mixture was analyzed for (TG)₁₀ by HPLC (Shodex; 1 mL/min, 260 nm; isocratic, 0.1 M sodium phosphate, pH 7.5, 1 mM EDTA, 7.5% CH₃CN; *t_R* for 7a, 6.9 min, *t_R* for (TG)₁₀, 9.0 min). No excess (TG)₁₀ was observed, so an additional 430 OD₂₆₀ (16 mg, 2.3 μ mol) of (TG)₁₀ was added. The mixture was again heated to 70 °C and allowed

ELISA Assay for Anti-KLH. A sandwich-type ELISA was used to measure anti-KLH antibodies as determined by interpolation from a standard curve generated using a stan-

lard pool of anti-KLH plasma. The measurement of anti-KLH antibodies is expressed as a percent of the standard pool.

References

- (1) (a) Nossal, G. J. V.; Pike, B. L.; Katz, D. H. Induction of B Cell Tolerance *in vitro* to 2,4-Dinitrophenyl Coupled to a Copolymer of D-Glutamic Acid and D-Lysine (DNP-D-GL). *J. Exp. Med.* 1973, 138, 312-317. (b) Liu, F.-T.; Zinnecker, M.; Hamaoka; Katz, D. H. New Procedures for Preparation and Isolation of Conjugates of Proteins and a Synthetic Copolymer of D-Amino Acids and Immunochemical Characterization of Such Conjugates. *Biochemistry* 1979, 18, 690-697.
- (2) Smeenk, R. J. T.; Brinkman, K.; van den Brink, H. G.; Westgeest, A. A. A. Reaction Patterns of Monoclonal Antibodies to DNA. *J. Immunol.* 1988, 140, 3786-3792.
- (3) Conrad, M. J.; Coutts, S. M. Conjugates of Biologically Stable Polyfunctional Molecules and Polynucleotides for Treating Systemic Lupus Erythematosus. U.S. Patent 5,272,013, 1994.
- (4) Jones, D. S.; Hachmann, J. P.; Osgood, S. A.; Hayag, M. S.; Barstad, P. A.; Iverson, G. M.; Coutts, S. M. Conjugates of Double Stranded Oligonucleotides with Polyethylene Glycol and Keyhole Limpet Hemocyanin: A Model for Treating Systemic Lupus Erythematosus. *Bioconjugate Chem.* 1994, 5, 390-399.
- (5) The convention used herein to describe repeating dimers of deoxynucleotides is exemplified as follows. The 20-mer ON, (CA)₁₀, is an alternating sequence of deoxycytidine and deoxyadenosine with deoxycytidine at the 5'-end. The 50-mer ON, (CA)₂₅, is an alternating sequence of deoxycytidine and deoxyadenosine with deoxycytidine at the 5'-end. Similarly, (TG)₁₀ is a 20-mer ON with deoxythymidine at the 5'-end, and (TG)₂₅ is a 50-mer ON with deoxythymidine at the 5'-end.
- (6) Experiments with different sequences of synthetic oligonucleotide duplexes demonstrated sequence dependence on binding to anti-ds-DNA from lupus mice and humans, as detected by competitive inhibition assays with high molecular weight DNA. This was apparently related to the stability of the duplex and its propensity to assume the B DNA conformation. The duplex formed from (CA)₂₅ and (TG)₂₅, under physiological conditions, assumes the B DNA conformation as evidenced by CD spectroscopy.
- (7) Dintzis, H. M.; Dintzis, R. Z.; Vogelstein, B. Molecular Determinates of Immunogenicity: The Immunon Model of Immune Response. *Proc. Natl. Acad. Sci. U.S.A.* 1978, 73, 3671-3675.
- (8) (a) Jackson, A. E.; Johnstone, R. A. W. Rapid, Selective Removal of Benzoyloxycarbonyl Groups from Peptides by Catalytic Transfer Hydrogenation. *Synthesis* 1976, 685-687. (b) Anantharamaiah, G. M.; Sivanandaiah, K. M. Transfer Hydrogenation; A Convenient Method for Removal of Some Commonly Used Protecting Groups in Peptide Synthesis. *J. Chem. Soc., Perkin Trans. 1* 1977, 490-491.
- (9) Shames, S. L.; Byers, L. D. Acyl Substituent Effects on Rates of Acyl Transfer to Thiolate, Hydroxide, and Oxy Dianions. *J. Am. Chem. Soc.* 1981, 103, 6170-6177.
- (10) Sani, B. P.; Vaid, A.; Cory, J. G.; Brockman, R. W.; Elliott, R. D.; Montgomery, J. A. 5'-Haloacetamido-5'-Deoxythymidines: Novel Inhibitors of Thymidylate Synthase. *Biochim. Biophys. Acta* 1986, 881, 175-184.
- (11) Guar, R. K. Introduction of 5' Terminal Amino and Thio Groups into Synthetic Oligonucleotides. *Nucleosides Nucleotides* 1991, 10, 895-909. Connolly, B. A. Chemical Synthesis of Oligonucleotides Containing a Free Sulphydryl Group and Subsequent Attachment of Thiol Specific Probes. *Nucleic Acids Res.* 1985, 13, 4485-4502. Ansorge, W.; Sproat, B.; Stegemann, J.; Schwager, C.; Zenke, M. Automated DNA Sequencing: Ultrasensitive Detection of Fluorescent Bands During Electrophoresis. *Nucleic Acids Res.* 1987, 15, 4593-4602. Sproat, B. S.; Beigher, B.; Rider, P.; Neuner, P. The Synthesis of Protected 5'-Mercapto-2',5'-dideoxyribonucleoside-3'-O-phosphoramidites; Uses of 5'-Mercapto-oligodeoxyribonucleotides. *Nucleic Acids Res.* 1987, 15, 4837-4848. Li, P.; Medon, P.; Skingle, D. C.; Lanser, J. A.; Symons, R. H. Enzyme-linked Synthetic Oligonucleotide Probes: Non-radioactive Detection of Enterotoxigenic *Escherichia coli* in Faecal Specimens. *Nucleic Acids Res.* 1987, 15, 5275-5287. Asseline, U.; Bonfils, E.; Kurtürst, R.; Chassignol, M.; Roig, V.; Thuong, N. T. Solid-Phase Preparation of 5',3'-Heterobifunctional Oligodeoxyribonucleotides Using Modified Solid Supports. *Tetrahedron* 1992, 48, 1233-1254.
- (12) Burns, J. A.; Butler, J. C.; Moran, J.; Whitesides, G. M. Selective Reduction of Disulfides by Tris(2-carboxyethyl)phosphine. *J. Org. Chem.* 1990, 55, 2648-2650 and references therein.
- (13) Precipitation of the thiol-containing oligonucleotide removes tributylphosphine, tributylphosphine oxide, and O-trityl-6-mercaptohexan-1-ol, the other half of the disulfide.
- (14) HPLC analyses were carried out using a GenPak FAX column (1 mL/min, gradient, 30-70% B (A = 0.05 M pH 7.5 sodium phosphate in 10% MeOH, B = 0.05 M pH 7.5 sodium phosphate and 1.0 M NaCl in 10% MeOH) 0-16 min, 260 nm).
- (15) The reactions were run in 100 mM pH 10 sodium borate buffer at 25 °C. The concentration of 5 was kept at 25 mg/mL, and
- (16) Sequencing was done by a modification of the method of Maxam and Gilbert,²⁷ using 3'-end labeling with terminal transferase and [³²P]dideoxy-ATP. Thus 1 μL of oligonucleotide-containing solution (5.28 μg), 4 μL of 5X terminal transferase buffer (Promega), 5 μL of [³²P]dideoxy-ATP (Amersham), 9 μL of H₂O, and 1 μL of terminal transferase solution (Amersham) were incubated for 30 min at 37 °C. The mixture was desalted on a PD-10 gel filtration column (Pharmacia). Fractions containing oligonucleotide were concentrated to dryness and dissolved in 50 μL of H₂O. Chemical cleavage was performed on 10 μL of the mixture using standard Maxam-Gilbert techniques. The cleavage mixtures were analyzed on a 20% polyacrylamide gel.
- (17) An oligonucleotide of this size is near the limit for routine application of the electrospray technique. The mass spectrum of 6a was obtained from the Mass Spectroscopy Lab at the Scripps Institute, La Jolla, CA, using a API III Perkin Elmer Sciex triple-quadrupole mass spectrometer with a Tune data system and MacSpec reconstruct program to calculate the molecular weight. A sodium-free sample was prepared for mass spectrometry by dialyzing extensively with 0.1 M pH 6.5 triethylammonium borate followed by dialysis with water. The dialysate was lyophilized to a solid. Reconstruction of molecular ion peaks from fragments showed a broad series of peaks centered at 25 720 mass units, with a width at half-height of 130 mass units.
- (18) Quantitation of oligonucleotides was conveniently determined by measuring optical density at 260 nm (OD₂₆₀). Absorbances were measured on dilute solutions which had an absorbance less than 1.0 in pH 7.2 PBS. Optical density was determined by multiplying absorbance by the dilution factor. The molar extinction coefficient for 6a at 260 nm was determined by three methods: (1) phosphorus determination assuming 80 mol of phosphorus for 1 mol of 6a, (2) carbon combustion analysis assuming a chemical formula of C₁₃₂H₁₀₁₆N₁₃₀O₄₅₄P₈₀Na₈₀Se₄, and (3) determination of specific activity for ¹⁴C-labeled 6b assuming the specific activity of 6b to be 212 mCi/mmol (4 times the specific activity of the ¹⁴C-labeled bromoacetic acid used in its preparation). The values determined by the three methods were in close agreement (within 3%), with the mean being 715 668 ± 15 096 M⁻¹ cm⁻¹ (26.11 ± 0.55 mL mg⁻¹ cm⁻¹). The molar extinction coefficient for 7a was determined by three methods: (1) phosphorus determination assuming 156 mol of phosphorus for 1 mol of LJP 394, (2) carbon combustion analysis assuming a chemical formula of C₁₃₂H₁₁₄₄N₁₄₀O₅₇₀P₁₅₆Se₄, and (3) determination of specific activity for ¹⁴C-labeled 7b assuming the specific activity of 7b to be 212 mCi/mmol. The values determined by the three methods were in close agreement, with the mean being 1 208 962 ± 26 971 M⁻¹ cm⁻¹ (22.25 ± 0.56 mL mg⁻¹ cm⁻¹).
- (19) Chen, P. S.; Toribara, T. Y.; Warner, H. Microdetermination of Phosphorus. *Anal. Biochem.* 1956, 28, 1756-1758.
- (20) Ferguson, T. A.; Beaman, K. D.; Iverson, G. M. Isolation and Characterization of a T Suppressor Factor by Using a Monoclonal Antibody. *J. Immunol.* 1985, 134, 3163-3171.
- (21) Garvey, J. S.; Cremer, N. E.; Sussdorf, D. H. *Methods in Immunology*, 3rd ed.; W.A. Benjamin, Inc.: Reading, MA, 1976; pp 301-312.
- (22) Maxam, A.; Gilbert, W. A New Method for Sequencing DNA. *Proc. Natl. Acad. Sci. U.S.A.* 1977, 74, 560-564. Maxam, A. M.; Gilbert, W. Sequencing End-labeled DNA with Base-specific Chemical Cleavages. *Methods Enzymol.* 1980, 65, 499-560.
- (23) It is important to use highly purified 4 in the conjugation process because any reactive impurity becomes amplified by a factor of 4, manifested as an impurity in the tetrasubstituted conjugate 6a. For example, a 5% impurity in 4, if reactive, would produce a 20% impurity in 6a. Analytical reversed phase HPLC was performed on fractions collected in the anion exchange column purification of 4, and only fractions of >90% purity were used. This resulted in a final purity of 95%.
- (24) Iverson, G. M. Assay for *in vivo* adoptive immune response. In *Handbook of Experimental Immunology, Volume 2: Cellular Immunology*, 4th ed.; Eir, D. M., Herzenberg, L. A., Blackwell, C., Herzenberg, L. A., Eds.; Blackwell Scientific Publications: Oxford, 1986; Chapter 67, pp 67.1-67.8.
- (25) Henry, C. Hemolytic Plaque Assay. In *Selected Methods in Cellular Immunology*; Mishell, B. B., Shiigi, S. M., Eds.; W. H. Freeman and Co.: San Francisco, CA, 1980; Chapter 3, pp 69-123.
- (26) Fontanel, M. L.; Bazin, H.; Roget, A.; Teoule, R. Synthesis and Use of 4-Hydroxyphenyl Derivatized Phosphoramidites in the Selective Radiolabeling of Oligonucleotide Probes. *J. Labelled Compd. Radiopharm.* 1993, 33, 717-724.
- (27) Mitchison, N. A. The Carrier Effect in the Secondary Response to Hapten-Protein Conjugates. (1) Measurement of the Effect and Objections to the Local Environment Hypothesis. *Eur. J. Immunol.* 1971, 1, 10.